Group 1 - Shares of Braze, Inc. (BRZE) have increased by 10.8% over the past four weeks, closing at $33.66, with a mean price target of $51.37 indicating a potential upside of 52.6% [1] - The mean estimate consists of 19 short-term price targets with a standard deviation of $10.18, where the lowest estimate is $38 (12.9% increase) and the highest is $75 (122.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 0.7% over the past month, with two estimates increasing and one decreasing [12] - BRZE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Copa Holdings (CPA) closed the last trading session at $100.68, gaining 19% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $150.45 indicates a 49.4% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $20.25. While the lowest estimate of $120 indicates a 19.2% increase from the current price level, the most optimistic analyst expec ...

Roku (ROKU) closed the last trading session at $61.36, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $88.87 indicates a 44.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $17.78. While the lowest estimate of $60 indicates a 2.2% decline from the current price level, the most optimistic analyst expects the stock ...

Group 1 - The stock of Pros Holdings (PRO) closed at $16.87, reflecting a 2.1% gain over the past four weeks, with a mean price target of $28.86 indicating a potential upside of 71.1% [1] - The average price targets from analysts range from a low of $22 to a high of $38, with a standard deviation of $5.98, suggesting a variability in estimates; the lowest estimate indicates a 30.4% increase, while the highest suggests a 125.3% upside [2] - Analysts show a consensus that PRO will report better earnings than previously estimated, which is a positive indicator for potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 18.9% over the last 30 days, with three estimates moving higher and no negative revisions [12] - PRO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [13]

Group 1 - The stock of Priority Technology (PRTH) closed at $6.71, with a 2.1% gain over the past four weeks, and analysts set a mean price target of $12.80, indicating a potential upside of 90.8% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $2.77, where the lowest estimate is $10 (49% increase) and the highest is $16 (138.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9% over the past month, indicating positive sentiment among analysts [12] - PRTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Group 1: Financial Performance - InspireMD, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -29.41% [1] - The company posted revenues of $1.53 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.21%, and showing a slight increase from year-ago revenues of $1.51 million [2] - Over the last four quarters, InspireMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - InspireMD shares have declined approximately 1.1% since the beginning of the year, while the S&P 500 has seen a decline of -3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.93 million, and for the current fiscal year, it is -$0.79 on revenues of $8.22 million [7] - The estimate revisions trend for InspireMD is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Adeia (ADEA) shares have increased by 4.4% over the past four weeks, closing at $13.10, with a mean price target of $17.33 indicating a potential upside of 32.3% [1] - The average price targets range from a low of $17 to a high of $18, with a standard deviation of $0.58, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about ADEA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for ADEA's current year earnings has increased by 1% over the past month, with no negative revisions [12] - ADEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Core Viewpoint - Novo Nordisk (NVO) shows potential for significant upside, with a mean price target of $102.16 indicating a 51.2% upside from the current price of $67.55 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from $61 to $160, with a standard deviation of $36.83, indicating variability among analysts [2] - The lowest estimate suggests a decline of 9.7%, while the highest points to a 136.9% upside [2] - Analysts' price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Market Sentiment - Analysts are optimistic about NVO's earnings prospects, with a trend of upward revisions in EPS estimates, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.4%, with three estimates moving higher and no negative revisions [12] - NVO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [13]

Group 1 - Si-Bone (SIBN) shares have increased by 25.5% over the past four weeks, closing at $17.47, with a mean price target of $24.67 indicating a potential upside of 41.2% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $3.57, where the lowest estimate is $19 (an 8.8% increase) and the highest is $32 (an 83.2% increase) [2] - Analysts show strong agreement on SIBN's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for SIBN has increased by 7% due to four upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - SIBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While price targets can be misleading, the direction implied by them may serve as a useful guide for further research into SIBN's fundamentals [10][11]

Shares of Immunome, Inc. (IMNM) have gained 19.7% over the past four weeks to close the last trading session at $7.43, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26 indicates a potential upside of 249.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.26. While the lowest estimate of $20 indicates a 169.2% increase from the curren ...